Sign up for MarketBeat All Access to get access to all of MarketBeat’s research tools:
Fulgent Genetics (NASDAQ: FLGT) target price was announced by equity researchers at Piper Sandler in a Friday to the Investor-facing notice increased from $ 135.00 to $ 140.00, reports The Fly. The company currently has an « overweight » rating on the stock. Piper Sandler’s price target would indicate a potential 63.69% gain over the stock’s last closing price.
Other equity analysts recently released research on the stock. Zacks Investment Research upgraded Fulgent Genetics’ shares from a « Hold » rating to a « Strong Buy » rating and set a price target of $ 137.00 on the stock in a research report on Friday, February 5th . Credit Suisse Group downgraded Fulgent Genetics shares from a « neutral » rating to an « underperform » rating and lowered its price target for the share from $ 42.00 to $ 40.00 in a report on Friday, January 8th USD. BTIG Research downgraded Fulgent Genetics shares from a « buy » rating to a « neutral » rating in a report on Tuesday, November 24th. TheStreet raised the shares of Fulgent Genetics from a « c » rating to a « b- » rating in a report on Friday, November 13th. Finally, Oppenheimer raised the price target for shares of Fulgent Genetics from USD 75.00 to USD 130.00 and rated the shares as « Outperform » in a report on Monday, February 1st. A research analyst has rated the stock with a sell rating, two with a hold rating, two with a buy rating, and one with a strong buy rating. The stock has an average rating of « Buy » and a consensus price target of $ 84.83.
NASDAQ: FLGT shares opened at $ 85.53 on Friday. The stock has a market cap of $ 2.08 billion, a P / E of 42.34, and a beta of 1.92. The company’s 50-day moving average is $ 112.38 and the 200-day moving average is $ 59.34. Fulgent Genetics has a 52-week low of $ 6.70 and a 52-week high of $ 189.89. (adsbygoogle = window.adsbygoogle || []). push ({});
Fulgent Genetics (NASDAQ: FLGT) last published its results on Wednesday, March 3rd. The company reported earnings per share of $ 6.20 for the quarter, beating analysts’ consensus estimate of $ 4.36 by $ 1.84. The company posted revenue of $ 294.98 million for the quarter, compared to analyst expectations of $ 199.38 million. Fulgent Genetics had a net margin of 35.31% and a return on equity of 43.81%. The company’s sales increased 3417.1% over the previous year. On average, stock analysts predict that Fulgent Genetics will post an EPS of 4.08 for the current fiscal year. In other news, CFO Paul Kim sold 10,662 shares of Fulgent Genetics stock in a transaction dated Wednesday, December 9th. The shares were sold at an average price of $ 51.60 for a total transaction of $ 550,159.20. Following the sale, the CFO now holds 191,521 shares in the company, valued at approximately $ 9,882,483.60. The sale was announced in a legal filing with the Securities & Exchange Commission, which is available on the SEC website. Insiders own 45.00% of the company’s stock.
Several institutional investors and hedge funds recently changed their positions in FLGT. Steward Partners Investment Advisory LLC acquired a new stake in Fulgent Genetics worth approximately $ 58,000 in the third quarter. Comerica Bank bought a new stake in Fulgent Genetics worth approximately $ 439,000 in the third quarter. BNP Paribas Arbitrage SA increased its stake in Fulgent Genetics by 545.9% in the third quarter. BNP Paribas Arbitrage SA now owns 2,338 shares in the company valued at $ 94,000 after purchasing an additional 1,976 shares in the most recent quarter. Meeder Asset Management Inc. acquired a new stake in Fulgent Genetics worth approximately $ 41,000 in the third quarter. Eventually, the Oregon Public Employees Retirement Fund bought a new stake in Fulgent Genetics worth approximately $ 192,000 in the third quarter. Currently, 33.39% of the company’s shares are owned by hedge funds and other institutional investors.
Fulgent Genetics, Inc and its affiliates provide genetic testing to physicians with clinically useful diagnostic information. The technology platform integrates data comparison and suppression algorithms, adaptive learning software, as well as genetic diagnostic tools and integrated laboratory processes.
This instant messaging alert was generated using narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate reporting possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send any questions or comments about this story to [email protected]
When you say Internet of Things (IoT), the answers you may get differently. I think of it broadly as a connection. It’s about devices that can connect to each other and to the Internet. And this provides users with the solutions that make our lives more comfortable.
The simplest and most ubiquitous example of an IoT device is the smartphone that many of us have with us at all times. But think about what that led to. Home assistants, surveillance cameras, fitness apps and much more are made possible by the Internet of Things.
The Internet of Things became even more important in the pandemic as companies had to find a way to keep their networks safe and viable, even if their employees were remotely dispersed. This created a demand for edge and cloud computing solutions, which the Internet of Things also facilitates.
And yes, this is just the beginning. The need for more and more data is driving the demand for IoT solutions in areas such as autonomous vehicles.
The good news, however, is that this area is still in the growth phase. And that means there is no shortage of companies you can find to trade in this sector. To help you get started, we’ve put together this special presentation that introduces seven such companies and the reasons we think they deserve to be included in your portfolio.
Check out the « 7 Internet of Things stocks that perfectly fit our connected future ».
Fill out the form below to get the latest headlines and analyst recommendations for your stocks with our free daily Receive Email Newsletters:
Sign up to MarketBeat All Access to get access to all of MarketBeat’s research tools:
View the latest news, buy / sell ratings, SEC filings and insider trading on your stocks. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.
Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.
Identify stocks that match your criteria using seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access Stock Screener, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.
Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.
© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Don’t sell my information
© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. The information is provided « as is » and is provided for informational purposes only, not for commercial or advisory purposes, and is delayed. Please refer to the disclaimer for all delays and terms of use for exchanges. Basic company data from Zacks Investment Research. As a bonus for subscribing to our e-mail newsletters, you will also receive a free subscription to the Liberty Through Wealth e-newsletter. You can unsubscribe at any time.
Enter your email address below to receive a quick daily summary of upgrades, downgrades, and new coverage from Analysts with MarketBeat.com’s FREE daily email newsletter.
Ref: https://www.marketbeat.com
